KG acted as Greek legal advisor to Novartis on the separation of Sandoz, its generic and biosimilars division in Greece. The local transaction was part of the global separation and spin-off of Sandoz, which was completed on 4 October 2023. As a consequence, Sandoz has become an independent, publicly traded company on the SIX Swiss Exchange with ADRs traded on the over-the-counter market in the US.
The local transaction was completed on February 1st, 2024, from which date onwards Sandoz Hellas Single Member S.A. shall market the generic and biosimilar products of Sandoz in the Greek market.
The KG’s Corporate and M&A team was led by Claire Pavlou, Partner, Katerina Tzamalouka, Counsel and Aggelos Kosteletos, Associate.
You may find more information on the following links: